Acute Coronary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Few studies have investigated the relationship between PCSK9 levels and the severity of coronary artery disease in patients with acute coronary syndrome; thus, we herein aimed to investigate this relationship in patients with non-ST-elevation myocardial infarction (NSTEMI) who underwent coronary angiography.
|
31206403 |
2020 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Potential use of PCSK9 inhibitors as a secondary preventative measure for cardiovascular disease following acute coronary syndrome: a UK real-world study.
|
30709868 |
2019 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy.
|
31121022 |
2019 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, despite intensive statin therapy, targeting LDL-C levels of 25 to 50 mg/dL and avoiding sustained LDL-C <15 mg/dL.
|
31707788 |
2019 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) trial provide additional support that a PCSK9 inhibitor can be initiated safely and effectively early after an acute coronary syndrome.
|
31741082 |
2019 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effect on fibrous-cup thickness, or extension of the atherosclerotic plaque with PCSK9-inhibitor, for several weeks after onset of acute coronary syndrome (ACS) has never been reported.
|
31495548 |
2019 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome is unknown.
|
31272931 |
2019 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In patients with acute coronary syndromes (ACSs) treated with P2Y<sub>12</sub> inhibitors, a direct association between PCSK9 serum levels and residual platelet reactivity was found.
|
30605918 |
2019 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the association between plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations, current acute coronary syndrome (ACS), coronary artery disease (CAD) presence, severity and extension and the burden of coronary calcifications in patients with suspected CAD.
|
31493378 |
2019 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy.
|
30403574 |
2018 |
Acute Coronary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The study endpoint was to determine whether PCSK9 serum levels prior to CEA would predict the occurrence of acute coronary syndromes (ACS) at 24-month follow-up.
|
29754909 |
2018 |
Acute Coronary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome.
|
29885102 |
2018 |
Acute Coronary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome.
|
30112872 |
2018 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials.
|
28482694 |
2017 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study.
|
27810295 |
2017 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aim to assess in the real world the suitability of PCSK9 inhibitors for acute coronary syndromes.
|
29122809 |
2017 |
Acute Coronary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study aims to investigate the correlation between serum PCSK9 levels and coronary damage severity in patients hospitalized for acute coronary syndrome (ACS).
|
28865748 |
2017 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Before our study, there were no data concerning complex evaluation of: plasma PCSK9 concentrations, transcript LDL receptor (LDLR), as well as the total amount of monocytes' LDLR in acute coronary syndrome (ACS) patients.
|
27665855 |
2016 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three large phase III programmes with the new anti PCSK9 antibodies are currently underway in patients with acute coronary syndrome (ACS) and LDL-C inadequately controlled by standard treatments.
|
25856746 |
2015 |